
NeoGenomics (NEO) Stock Forecast & Price Target
NeoGenomics (NEO) Analyst Ratings
Bulls say
NeoGenomics is poised for strong growth, with its 85% clinical services division utilizing its state-of-the-art laboratories and broad test menu to cater to the rapidly growing demand for oncology diagnostic testing. While the company faces challenges in integrating acquired businesses and navigating complex regulatory environments, it has strong potential for growth in its competitive landscape. Additionally, its recent financial results have been in line with expectations and its optimistic outlook for the future, including continued double-digit growth and potential margin expansion, makes it an attractive investment opportunity.
Bears say
NeoGenomics is facing unpredictability in public and private reimbursement, as well as pressure to remain competitive against sophisticated lab competitors, leading to potential lower margins as competitors gain share of the market. The company's recent launch of the RaDaR ST MRD test and plans to expand its indications in the second half of 2026 may drive revenue growth, but this could be offset by increased expenses from sales force expansion and integration of acquisitions. The company's financial results for the second quarter of 2026 will be a key indication of its ability to execute on its plans and maintain competitive positioning in the market.
This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.
NeoGenomics (NEO) Analyst Forecast & Price Prediction
Start investing in NeoGenomics (NEO)
Order type
Buy in
Order amount
Est. shares
0 shares